Home > Gastroenterology > ECCO 2021 > Improvements in Small Molecules > Promising safety and pharmacokinetic data on BT051 for UC

Promising safety and pharmacokinetic data on BT051 for UC

Presented By
Dr Chris Stevens, Bacainn Therapeutics, Clinical Development, Concord, United States
ECCO 2021
Phase 1
BT051, a drug in clinical development for the treatment of ulcerative colitis (UC), was safe and well tolerated in the healthy subject population of a phase 1, randomised, double-blind trial. Moreover, the drug demonstrated very limited systemic exposure. The results support the further development of BT051 as a potential gut-targeted therapy for patients with UC. BT051 is an oral, non-systemic, multidrug resistance-associated protein 2 (MRP2)/formyl peptide receptor 1 (FRP1) antagonist. The drug targets gut neutrophil activity. To assess the safety, tolerability, and pharmacokinetics of BT051, healthy subjects were enrolled in five BT051 ascending single-dose cohorts (n=40) or placebo (n=10) [1]. The lowest administered dose was 100 mg, the highest dose was 3,500 mg. Participants were followed until 30 days post-dose. Adverse events (AEs) occurred equally often in the BT051 cohorts and placebo group, with 22.5% and 20% of the subje...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on